Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 10, 2017
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining how the location of mitral valve prolapse (a condition where the mitral valve does not close properly) affects the long-term success of a surgical procedure called mitral plasty. Mitral valve prolapse can lead to a condition called mitral insufficiency, where the heart cannot pump blood effectively. The researchers want to understand how different types of prolapse—whether it's on one part of the valve or both—impact the outcomes of the surgery.
To participate in this study, patients must have undergone mitral surgery between 1988 and 2011 and have been diagnosed with mitral valve prolapse through an ultrasound of the heart. Those with certain heart conditions or previous heart surgeries will not be eligible. If you join the study, you can expect to provide information about your health and the surgery you had, helping researchers learn more about the best treatment approaches for this condition. This trial is currently looking for participants of all genders, aged 65 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients operated between 1988 and 2011
- • Presence of a valvular prolapse diagnosed by echocardiography
- • Possibility of a complete clinical evaluation at the time of the initial echocardiography
- Exclusion Criteria:
- • Ischemic MI (including papillary muscle rupture)
- • Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease
- • History of cardiac surgery
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, Picardie, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials